Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Fabrice Andre"'
Autor:
Henry NL; N. Lynn Henry, MD, PhD, University of Michigan, Ann Arbor, MI; Fabrice Andre, MD, PhD, Institute Gustave Roussy, Paris Sud University, Paris, France; Nofisat Ismaila, MD; Mark R. Somerfield, PhD, American Society of Clinical Oncology, Alexandria, VA; and Vered Stearns, MD, Johns Hopkins University School of Medicine, Baltimore, MD., Andre F; N. Lynn Henry, MD, PhD, University of Michigan, Ann Arbor, MI; Fabrice Andre, MD, PhD, Institute Gustave Roussy, Paris Sud University, Paris, France; Nofisat Ismaila, MD; Mark R. Somerfield, PhD, American Society of Clinical Oncology, Alexandria, VA; and Vered Stearns, MD, Johns Hopkins University School of Medicine, Baltimore, MD., Ismaila N; N. Lynn Henry, MD, PhD, University of Michigan, Ann Arbor, MI; Fabrice Andre, MD, PhD, Institute Gustave Roussy, Paris Sud University, Paris, France; Nofisat Ismaila, MD; Mark R. Somerfield, PhD, American Society of Clinical Oncology, Alexandria, VA; and Vered Stearns, MD, Johns Hopkins University School of Medicine, Baltimore, MD., Somerfield MR; N. Lynn Henry, MD, PhD, University of Michigan, Ann Arbor, MI; Fabrice Andre, MD, PhD, Institute Gustave Roussy, Paris Sud University, Paris, France; Nofisat Ismaila, MD; Mark R. Somerfield, PhD, American Society of Clinical Oncology, Alexandria, VA; and Vered Stearns, MD, Johns Hopkins University School of Medicine, Baltimore, MD., Stearns V; N. Lynn Henry, MD, PhD, University of Michigan, Ann Arbor, MI; Fabrice Andre, MD, PhD, Institute Gustave Roussy, Paris Sud University, Paris, France; Nofisat Ismaila, MD; Mark R. Somerfield, PhD, American Society of Clinical Oncology, Alexandria, VA; and Vered Stearns, MD, Johns Hopkins University School of Medicine, Baltimore, MD.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Jan 01; Vol. 38 (1), pp. 102-103. Date of Electronic Publication: 2019 Nov 01.
Autor:
Krop I; Ian Krop, Dana-Farber Cancer Institute, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Fabrice Andre, Institute Gustave Roussy, Paris, France; Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Baylor University Medical Center, Texas Oncology PA, Dallas, TX; William Barlow, Cancer Research and Biostatistics, Seattle, WA; Deborah E. Collyar, Patient Advocates in Research, Danville, CA; M. Elizabeth Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; Catherine Van Poznak, University of Michigan, Ann Arbor, MI; and Antonio C. Wolff and Vered Stearns, Johns Hopkins University, Baltimore, MD., Ismaila N; Ian Krop, Dana-Farber Cancer Institute, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Fabrice Andre, Institute Gustave Roussy, Paris, France; Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Baylor University Medical Center, Texas Oncology PA, Dallas, TX; William Barlow, Cancer Research and Biostatistics, Seattle, WA; Deborah E. Collyar, Patient Advocates in Research, Danville, CA; M. Elizabeth Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; Catherine Van Poznak, University of Michigan, Ann Arbor, MI; and Antonio C. Wolff and Vered Stearns, Johns Hopkins University, Baltimore, MD., Andre F; Ian Krop, Dana-Farber Cancer Institute, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Fabrice Andre, Institute Gustave Roussy, Paris, France; Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Baylor University Medical Center, Texas Oncology PA, Dallas, TX; William Barlow, Cancer Research and Biostatistics, Seattle, WA; Deborah E. Collyar, Patient Advocates in Research, Danville, CA; M. Elizabeth Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; Catherine Van Poznak, University of Michigan, Ann Arbor, MI; and Antonio C. Wolff and Vered Stearns, Johns Hopkins University, Baltimore, MD., Bast RC; Ian Krop, Dana-Farber Cancer Institute, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Fabrice Andre, Institute Gustave Roussy, Paris, France; Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Baylor University Medical Center, Texas Oncology PA, Dallas, TX; William Barlow, Cancer Research and Biostatistics, Seattle, WA; Deborah E. Collyar, Patient Advocates in Research, Danville, CA; M. Elizabeth Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; Catherine Van Poznak, University of Michigan, Ann Arbor, MI; and Antonio C. Wolff and Vered Stearns, Johns Hopkins University, Baltimore, MD., Barlow W; Ian Krop, Dana-Farber Cancer Institute, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Fabrice Andre, Institute Gustave Roussy, Paris, France; Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Baylor University Medical Center, Texas Oncology PA, Dallas, TX; William Barlow, Cancer Research and Biostatistics, Seattle, WA; Deborah E. Collyar, Patient Advocates in Research, Danville, CA; M. Elizabeth Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; Catherine Van Poznak, University of Michigan, Ann Arbor, MI; and Antonio C. Wolff and Vered Stearns, Johns Hopkins University, Baltimore, MD., Collyar DE; Ian Krop, Dana-Farber Cancer Institute, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Fabrice Andre, Institute Gustave Roussy, Paris, France; Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Baylor University Medical Center, Texas Oncology PA, Dallas, TX; William Barlow, Cancer Research and Biostatistics, Seattle, WA; Deborah E. Collyar, Patient Advocates in Research, Danville, CA; M. Elizabeth Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; Catherine Van Poznak, University of Michigan, Ann Arbor, MI; and Antonio C. Wolff and Vered Stearns, Johns Hopkins University, Baltimore, MD., Hammond ME; Ian Krop, Dana-Farber Cancer Institute, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Fabrice Andre, Institute Gustave Roussy, Paris, France; Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Baylor University Medical Center, Texas Oncology PA, Dallas, TX; William Barlow, Cancer Research and Biostatistics, Seattle, WA; Deborah E. Collyar, Patient Advocates in Research, Danville, CA; M. Elizabeth Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; Catherine Van Poznak, University of Michigan, Ann Arbor, MI; and Antonio C. Wolff and Vered Stearns, Johns Hopkins University, Baltimore, MD., Kuderer NM; Ian Krop, Dana-Farber Cancer Institute, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Fabrice Andre, Institute Gustave Roussy, Paris, France; Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Baylor University Medical Center, Texas Oncology PA, Dallas, TX; William Barlow, Cancer Research and Biostatistics, Seattle, WA; Deborah E. Collyar, Patient Advocates in Research, Danville, CA; M. Elizabeth Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; Catherine Van Poznak, University of Michigan, Ann Arbor, MI; and Antonio C. Wolff and Vered Stearns, Johns Hopkins University, Baltimore, MD., Liu MC; Ian Krop, Dana-Farber Cancer Institute, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Fabrice Andre, Institute Gustave Roussy, Paris, France; Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Baylor University Medical Center, Texas Oncology PA, Dallas, TX; William Barlow, Cancer Research and Biostatistics, Seattle, WA; Deborah E. Collyar, Patient Advocates in Research, Danville, CA; M. Elizabeth Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; Catherine Van Poznak, University of Michigan, Ann Arbor, MI; and Antonio C. Wolff and Vered Stearns, Johns Hopkins University, Baltimore, MD., Mennel RG; Ian Krop, Dana-Farber Cancer Institute, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Fabrice Andre, Institute Gustave Roussy, Paris, France; Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Baylor University Medical Center, Texas Oncology PA, Dallas, TX; William Barlow, Cancer Research and Biostatistics, Seattle, WA; Deborah E. Collyar, Patient Advocates in Research, Danville, CA; M. Elizabeth Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; Catherine Van Poznak, University of Michigan, Ann Arbor, MI; and Antonio C. Wolff and Vered Stearns, Johns Hopkins University, Baltimore, MD., Van Poznak C; Ian Krop, Dana-Farber Cancer Institute, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Fabrice Andre, Institute Gustave Roussy, Paris, France; Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Baylor University Medical Center, Texas Oncology PA, Dallas, TX; William Barlow, Cancer Research and Biostatistics, Seattle, WA; Deborah E. Collyar, Patient Advocates in Research, Danville, CA; M. Elizabeth Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; Catherine Van Poznak, University of Michigan, Ann Arbor, MI; and Antonio C. Wolff and Vered Stearns, Johns Hopkins University, Baltimore, MD., Wolff AC; Ian Krop, Dana-Farber Cancer Institute, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Fabrice Andre, Institute Gustave Roussy, Paris, France; Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Baylor University Medical Center, Texas Oncology PA, Dallas, TX; William Barlow, Cancer Research and Biostatistics, Seattle, WA; Deborah E. Collyar, Patient Advocates in Research, Danville, CA; M. Elizabeth Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; Catherine Van Poznak, University of Michigan, Ann Arbor, MI; and Antonio C. Wolff and Vered Stearns, Johns Hopkins University, Baltimore, MD., Stearns V; Ian Krop, Dana-Farber Cancer Institute, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Fabrice Andre, Institute Gustave Roussy, Paris, France; Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Baylor University Medical Center, Texas Oncology PA, Dallas, TX; William Barlow, Cancer Research and Biostatistics, Seattle, WA; Deborah E. Collyar, Patient Advocates in Research, Danville, CA; M. Elizabeth Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; Catherine Van Poznak, University of Michigan, Ann Arbor, MI; and Antonio C. Wolff and Vered Stearns, Johns Hopkins University, Baltimore, MD.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2017 Aug 20; Vol. 35 (24), pp. 2838-2847. Date of Electronic Publication: 2017 Jul 10.
Autor:
Nogova L; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Sequist LV; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Perez Garcia JM; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Andre F; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Delord JP; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Hidalgo M; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Schellens JH; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Cassier PA; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Camidge DR; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Schuler M; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Vaishampayan U; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Burris H; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Tian GG; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Campone M; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Wainberg ZA; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Lim WT; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., LoRusso P; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Shapiro GI; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Parker K; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Chen X; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Choudhury S; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Ringeisen F; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Graus-Porta D; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Porter D; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Isaacs R; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Buettner R; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland., Wolf J; Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2017 Jan 10; Vol. 35 (2), pp. 157-165. Date of Electronic Publication: 2016 Nov 21.
Autor:
Harris LN; Lyndsay N. Harris, National Cancer Institute, Bethesda, MD; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; National Cancer Institute, Bethesda, MD; and Fabrice Andre, Institute Gustave Roussy, Paris, France., Ismaila N; Lyndsay N. Harris, National Cancer Institute, Bethesda, MD; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; National Cancer Institute, Bethesda, MD; and Fabrice Andre, Institute Gustave Roussy, Paris, France., McShane LM; Lyndsay N. Harris, National Cancer Institute, Bethesda, MD; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; National Cancer Institute, Bethesda, MD; and Fabrice Andre, Institute Gustave Roussy, Paris, France., Andre F; Lyndsay N. Harris, National Cancer Institute, Bethesda, MD; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; National Cancer Institute, Bethesda, MD; and Fabrice Andre, Institute Gustave Roussy, Paris, France.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2016 Nov 10; Vol. 34 (32), pp. 3946-3948.
Autor:
Fribbens C; Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY., O'Leary B; Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY., Kilburn L; Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY., Hrebien S; Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY., Garcia-Murillas I; Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY., Beaney M; Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY., Cristofanilli M; Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY., Andre F; Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY., Loi S; Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY., Loibl S; Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY., Jiang J; Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY., Bartlett CH; Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY., Koehler M; Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY., Dowsett M; Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY., Bliss JM; Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY., Johnston SR; Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY., Turner NC; Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY. nicholas.turner@icr.ac.uk.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2016 Sep 01; Vol. 34 (25), pp. 2961-8. Date of Electronic Publication: 2016 Jun 06.
Autor:
Harris LN; Lyndsay N. Harris, Case Western Reserve University, Cleveland, OH; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Lisa M. McShane, National Cancer Institute, Bethesda, MD; Fabrice Andre, Institute Gustave Roussy, Paris, France; Deborah E. Collyar, Patient Advocates in Research; Elizabeth H. Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Ana M. Gonzalez-Angulo and Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G.Mennel, Baylor University Medical Center and Texas Oncology PA, Dallas, TX; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; and Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI., Ismaila N; Lyndsay N. Harris, Case Western Reserve University, Cleveland, OH; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Lisa M. McShane, National Cancer Institute, Bethesda, MD; Fabrice Andre, Institute Gustave Roussy, Paris, France; Deborah E. Collyar, Patient Advocates in Research; Elizabeth H. Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Ana M. Gonzalez-Angulo and Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G.Mennel, Baylor University Medical Center and Texas Oncology PA, Dallas, TX; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; and Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI. guidelines@asco.org., McShane LM; Lyndsay N. Harris, Case Western Reserve University, Cleveland, OH; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Lisa M. McShane, National Cancer Institute, Bethesda, MD; Fabrice Andre, Institute Gustave Roussy, Paris, France; Deborah E. Collyar, Patient Advocates in Research; Elizabeth H. Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Ana M. Gonzalez-Angulo and Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G.Mennel, Baylor University Medical Center and Texas Oncology PA, Dallas, TX; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; and Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI., Andre F; Lyndsay N. Harris, Case Western Reserve University, Cleveland, OH; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Lisa M. McShane, National Cancer Institute, Bethesda, MD; Fabrice Andre, Institute Gustave Roussy, Paris, France; Deborah E. Collyar, Patient Advocates in Research; Elizabeth H. Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Ana M. Gonzalez-Angulo and Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G.Mennel, Baylor University Medical Center and Texas Oncology PA, Dallas, TX; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; and Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI., Collyar DE; Lyndsay N. Harris, Case Western Reserve University, Cleveland, OH; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Lisa M. McShane, National Cancer Institute, Bethesda, MD; Fabrice Andre, Institute Gustave Roussy, Paris, France; Deborah E. Collyar, Patient Advocates in Research; Elizabeth H. Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Ana M. Gonzalez-Angulo and Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G.Mennel, Baylor University Medical Center and Texas Oncology PA, Dallas, TX; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; and Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI., Gonzalez-Angulo AM; Lyndsay N. Harris, Case Western Reserve University, Cleveland, OH; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Lisa M. McShane, National Cancer Institute, Bethesda, MD; Fabrice Andre, Institute Gustave Roussy, Paris, France; Deborah E. Collyar, Patient Advocates in Research; Elizabeth H. Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Ana M. Gonzalez-Angulo and Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G.Mennel, Baylor University Medical Center and Texas Oncology PA, Dallas, TX; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; and Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI., Hammond EH; Lyndsay N. Harris, Case Western Reserve University, Cleveland, OH; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Lisa M. McShane, National Cancer Institute, Bethesda, MD; Fabrice Andre, Institute Gustave Roussy, Paris, France; Deborah E. Collyar, Patient Advocates in Research; Elizabeth H. Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Ana M. Gonzalez-Angulo and Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G.Mennel, Baylor University Medical Center and Texas Oncology PA, Dallas, TX; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; and Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI., Kuderer NM; Lyndsay N. Harris, Case Western Reserve University, Cleveland, OH; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Lisa M. McShane, National Cancer Institute, Bethesda, MD; Fabrice Andre, Institute Gustave Roussy, Paris, France; Deborah E. Collyar, Patient Advocates in Research; Elizabeth H. Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Ana M. Gonzalez-Angulo and Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G.Mennel, Baylor University Medical Center and Texas Oncology PA, Dallas, TX; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; and Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI., Liu MC; Lyndsay N. Harris, Case Western Reserve University, Cleveland, OH; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Lisa M. McShane, National Cancer Institute, Bethesda, MD; Fabrice Andre, Institute Gustave Roussy, Paris, France; Deborah E. Collyar, Patient Advocates in Research; Elizabeth H. Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Ana M. Gonzalez-Angulo and Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G.Mennel, Baylor University Medical Center and Texas Oncology PA, Dallas, TX; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; and Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI., Mennel RG; Lyndsay N. Harris, Case Western Reserve University, Cleveland, OH; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Lisa M. McShane, National Cancer Institute, Bethesda, MD; Fabrice Andre, Institute Gustave Roussy, Paris, France; Deborah E. Collyar, Patient Advocates in Research; Elizabeth H. Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Ana M. Gonzalez-Angulo and Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G.Mennel, Baylor University Medical Center and Texas Oncology PA, Dallas, TX; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; and Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI., Van Poznak C; Lyndsay N. Harris, Case Western Reserve University, Cleveland, OH; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Lisa M. McShane, National Cancer Institute, Bethesda, MD; Fabrice Andre, Institute Gustave Roussy, Paris, France; Deborah E. Collyar, Patient Advocates in Research; Elizabeth H. Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Ana M. Gonzalez-Angulo and Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G.Mennel, Baylor University Medical Center and Texas Oncology PA, Dallas, TX; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; and Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI., Bast RC; Lyndsay N. Harris, Case Western Reserve University, Cleveland, OH; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Lisa M. McShane, National Cancer Institute, Bethesda, MD; Fabrice Andre, Institute Gustave Roussy, Paris, France; Deborah E. Collyar, Patient Advocates in Research; Elizabeth H. Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Ana M. Gonzalez-Angulo and Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G.Mennel, Baylor University Medical Center and Texas Oncology PA, Dallas, TX; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; and Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI., Hayes DF; Lyndsay N. Harris, Case Western Reserve University, Cleveland, OH; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Lisa M. McShane, National Cancer Institute, Bethesda, MD; Fabrice Andre, Institute Gustave Roussy, Paris, France; Deborah E. Collyar, Patient Advocates in Research; Elizabeth H. Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Ana M. Gonzalez-Angulo and Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G.Mennel, Baylor University Medical Center and Texas Oncology PA, Dallas, TX; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; and Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2016 Apr 01; Vol. 34 (10), pp. 1134-50. Date of Electronic Publication: 2016 Feb 08.
Autor:
Loibl S; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. sibylle.loibl@germanbreastgroup.de., von Minckwitz G; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Schneeweiss A; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Paepke S; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Lehmann A; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Rezai M; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Zahm DM; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Sinn P; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Khandan F; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Eidtmann H; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Dohnal K; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Heinrichs C; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Huober J; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Pfitzner B; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Fasching PA; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Andre F; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Lindner JL; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Sotiriou C; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Dykgers A; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Guo S; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Gade S; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Nekljudova V; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Loi S; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Untch M; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Denkert C; Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 Oct 10; Vol. 32 (29), pp. 3212-20. Date of Electronic Publication: 2014 Sep 08.
Autor:
Miller KD; Kathy D. Miller, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Reshma L. Mahtani, Sylvester Comprehensive Cancer Center, Miami, FL; Kathy S. Albain, Loyola University Chicago Stritch School of Medicine, Maywood, IL; Liang Fang, Glenn Michelson, Genentech, South San Francisco, CA; Howard A. Burris, Sarah Cannon Research Institute, Nashville, TN; Véronique Diéras, Institut Curie, Paris; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Nadia Harbeck, Interdisciplinary Breast Cancer, University of Cologne, Cologne; Nadia Harbeck, Breast Cancer University of Munich, Germany; Luca Gianni, San Raffaele Hospital, Milan; Diana Crivellari, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Italy; Sanne L. de Haas, F. Hoffmann-La Roche, Basel, Switzerland., Diéras V, Harbeck N, Andre F, Mahtani RL, Gianni L, Albain KS, Crivellari D, Fang L, Michelson G, de Haas SL, Burris HA
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 May 10; Vol. 32 (14), pp. 1437-44. Date of Electronic Publication: 2014 Apr 14.